Tagged with

recession Dr. Heitor Costa, Executive Director at Apifarm, Portugal, discusses the country’s economic situation and the presence of international pharmaceutical companies despite the recession. He further discusses the current policy and influence of generics on the pharmaceutical industry, and why he feels investment in Portugal is so crucial at a time…

Pharmaceutical Industry Baxter Spain’s general manager, Luigi Antoniazzi, discusses the challenges that the affiliate has faced in light of recent changes in the market, and the strategies taken to adapt to an ever-changing ecosystem for the pharmaceutical industry in the country. You became general manager of Baxter Spain & Portugal in 2011,…

Spain’s pharmaceutical industry has been under a lot of pressure in the past few years: public expenditure on pharmaceuticals contracted nearly 29 percent between May 2010 and December 2013. Numerous cost-containment measures, such as increases in co-payments, de-listing hundreds of minor medications and price cuts have all contributed to the…

Each year, the leading innovative pharmaceutical companies around the world lose revenues when the patents on their innovative drugs expire, and generics are allowed to replace them in the market. The table below shows how much money will be lost on currently existing patents by pharma companies around the world,…

generics   “The IMS Health figures show around three to four percent growth in the marketplace,” remarks Raymund Azurin, chief executive of Zuellig Pharma Philippines, “but we are now at a point in time where the business models in this market are changing. The rise of generics and increasing government intervention…

In PharmaBoardroom’s first coverage of Portugal in 2007, generics represented 16 percent of the country’s pharmaceutical market, a tremendous feat considering laws for generics had only been implemented a few years before. Today, generics represent nearly 40 percent of the market in units, with the aim is to increase this…

Russia This ranking for 2013 of the top 20 pharmaceutical products sold in the Russian hospital market during the year, organized by sales value, demoninates each drug according to its international nonproprietary name (INN), as denominated by the World Health Organization (WHO). Source: Pharmon / Aston Consulting

Russia As the rankings for the hospital market by sales value show, in Russia, it is multinational companies that dominate, with no local companies featuring on the top 20 ranking Source: Pharmon / Aston Consulting

Although the Polpharma group takes first place in the 2013 rankings of pharmaceutical companies in Poland when measured by sales, it is the only domestic company to make it into the top ten, which is dominated by multinationals.  

UAE “Over the past twenty years, we have seen a drastic change in the socio-economic climate of the Gulf region and neighboring countries. There has been considerable growth in terms of wealth and a sharp increase in health expenditures, which was mandated by the Ministry of Health”, explains Ayman Sahli, CEO…

  When PharmaBoardroom came to Portugal in 2007, price cuts, payment delays and changes to the health system with each successive government were but the first indications for the pharmaceutical sector that troubled times were ahead: four decades of political and financial mismanagement had resulted in Portugal’s economic stagnation. When…

Argentina Central nervous system, metabolic and cardiovascular products were the best performing therapeutic areas in Argentina in 2012, according to the graph below, which looks at market sales broken down by therapeutic area.